The Marquie Group Teams Up with City of Hope
The Marquie Group, Inc. (OTCMKTS: TMGI) has announced a remarkable partnership with City of Hope in the strive against metastatic triple-negative breast cancer (mTNBC). This initiative involves support for Dr. Peter P. Lee, M.D., who oversees the Immuno-Oncology Department at City of Hope, contributing to innovative cancer research aimed at using ivermectin as a potential treatment.
Innovative Research and Support for Cancer Treatment
This collaboration signifies a significant move towards tackling one of the most aggressive forms of breast cancer. The Marquie Group's commitment extends to donations from its subsidiary, Simply Whim, with 10% of sales directed towards Dr. Lee’s pioneering research. Furthermore, the company plans to leverage its Music of Your Life radio network to raise awareness and drive donations for the research efforts.
CEO Marc Angell’s Personal Motivation
Marc Angell, CEO of The Marquie Group, expressed how personal experiences fuel this initiative. “When our Simply Whim founder faced a diagnosis of metastatic triple-negative breast cancer, I was compelled to reach out to Dr. Lee, struck by his inspiring approach towards treatment. While ivermectin alone may not eradicate cancer, our research aims to explore its potential alongside other therapies,” said Angell. He underscored the necessity of funding for such studies, emphasizing the crucial role of collaborations in obtaining necessary financial support to advance groundbreaking cancer treatments.
Dr. Lee’s Research Journey
Currently, Dr. Lee's team is engaged in clinical trials, focusing specifically on mTNBC, which is known for its aggressive nature and limited treatment avenues. This research is pivotal as it investigates optimal dosages of ivermectin in combination with immunotherapy for affected patients. Dr. Lee expressed his gratitude towards Angell, highlighting his optimism about the research's potential to transform breast cancer treatment paradigms.
Funding and Awareness Campaigns Ahead
City of Hope has established dedicated resources to promote this cause. The upcoming campaign will allow listeners and supporters to contribute directly to Dr. Lee’s research, emphasizing The Marquie Group’s mission to create a meaningful impact in fighting cancer. This initiative showcases a commitment to enhance awareness regarding the critical need for funding in cancer research.
A Bright Future for Cancer Research
Through this collaboration, The Marquie Group aims to assist in overcoming financial barriers that often challenge groundbreaking research. The innovative work being done at City of Hope not only endeavors to advance treatment options for metastatic triple-negative breast cancer but reinforces the importance of community support in funding such critical studies. As efforts continue, the partnership stands as a beacon of hope in the fight against cancer.
Frequently Asked Questions
What is the goal of The Marquie Group's partnership with City of Hope?
The aim is to support innovative research focused on using ivermectin to treat metastatic triple-negative breast cancer.
How is The Marquie Group contributing financially to the research?
They are donating 10% of sales from their subsidiary, Simply Whim, to Dr. Lee’s research efforts.
What type of cancer is being targeted in this research?
The research focuses on metastatic triple-negative breast cancer, an aggressive subtype with limited treatment options.
Who is leading the research?
Dr. Peter P. Lee, M.D. is leading the research as the Chair of the Department of Immuno-Oncology at City of Hope.
How can people support the initiative?
Individuals can support the initiative by donating through dedicated channels provided by City of Hope, as well as purchasing products from Simply Whim.
